Compare Charles River Laboratories Intl. Inc (CRL) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs MPLX LP — how do they compare? Charles River Laboratories Intl. Inc trades at $232.4 (market cap $11.14B), while MPLX LP trades at $56.77 (market cap $57.34B). The key difference: MPLX LP is far larger — about 5.1× Charles River Laboratories Intl. Inc's market cap, and MPLX LP pays a 7.62% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | MPLX | |
|---|---|---|
Market Cap | $11.14B | $57.34B |
Sector | Health | Technology |
52-Week High | $233.60 | $59.17 |
52-Week Low | $145.57 | $47.80 |
Enterprise Value | $14.00B | $81.97B |
Dividend Yield | — | 7.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
MPLX trades at $57.21, up 0.46% today, with a bullish technical outlook supported by moving averages and a consensus price target of $60.60. The company reported strong profitability with a 41.24% net income margin and robust cash flow from operations of $5.91B in 2025. Recent earnings showed beats in Q3 and Q4 2025 but a miss in Q1 2026, with Q2 2026 results pending. A dividend of $1.08 was declared for H1-26, reinforcing income appeal.
The stock presents a compelling value with a P/E of 12.23 and high analyst buy consensus (71.43%), though risks include earnings volatility and high debt-to-asset ratio of 90.06%. Upside is supported by stable midstream operations and Permian Basin exposure, but investors should monitor Q2 2026 earnings for growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
